Introduction: Clinical trials of secukinumab have demonstrated their efficacy and safety in psoriatic arthritis as biological first choice or after inadequate response to other biological treatments.
Objective: To analyze the efficacy and safety of secukinumab in peripheral psoriatic arthritis over 12 months in real clinical practice.
Material And Methods: Patients with active peripheral psoriatic arthritis who started treatment with secukinumab according to the technical specifications were included. Efficacy and safety were evaluated from baseline to 12 months comparing naive and non-naive to biological therapy patients.
Results: A total of 76 patients were included (22 naive and 54 non-naive to biological) with an age of 51.9 years (10.3) and duration of the disease of 9.5 years (7.1). Of them, 31.6% with dactylitis, 51.3% with enthesitis and the baseline DAPSA was 19.0 (9.8). The retention rate was high, 90.9% in naive and 81.5% in non-naïve patients, and the percentage of patients with a DAPSA less than or equal to 14 was higher in the naive patients even after adjusting for age, sex and FAMEsc (P=.016). The safety data were similar to those described in the clinical trials.
Conclusions: Secukinumab is effective and safe in 12-month treatment in peripheral active psoriatic arthritis in real clinical practice, after inadequate response to TNF or as first biological treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.reuma.2019.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Refractory psoriatic arthritis: emerging concepts in whole process management.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Psoriatic arthritis (PsA) is a chronic and progressive inflammatory arthritis associated with psoriasis, mainly affecting the axial and peripheral joints, characterized by a wide range of complex phenotypes, significant heterogeneity, and a multifactorial etiology. To effectively address the distinct challenges in managing PsA, a pivotal emphasis is placed on clarifying the concept of refractory PsA. Here, we propose a distinction between refractory PsA, differentiating between difficult-to-treat PsA (D2T PsA) and Pseudo-D2T PsA.
View Article and Find Full Text PDFAssociation between TLR-2 and TLR-9 gene polymorphisms (rs5743708 and rs5743836) and susceptibility to psoriatic arthritis in Egyptian patients.
Egypt J Immunol
January 2025
Department of Dermatology and Venereology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Psoriasis (PsO) is a chronic immune-mediated disease of the skin. Psoriatic arthritis (PsA) is a prevalent chronic inflammatory disease that is associated with joint destruction and disability. The presence of PsO is the single greatest risk factor for the development of PsA.
View Article and Find Full Text PDFCertolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report.
SAGE Open Med Case Rep
January 2025
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Hidradenitis suppurativa is a chronic inflammatory disease of the skin with a suppurative-cicatricial outcome affecting the infundibular component of the pilo-sebaceous unit. The lesions are typically localized in the intertriginous and apocrine gland-rich areas. Hidradenitis suppurativa mainly affects patients at a young age and is very often refractory to conventional medical treatment.
View Article and Find Full Text PDFReal-World Data From the Joint Psoriasis-Psoriatic Arthritis Clinic (PPAC) on the Efficacy of Bimekizumab in Patients With Psoriasis and Psoriatic Arthritis.
Int J Dermatol
January 2025
Second Department of Dermatology and Venereology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
"Excluding Myself From What I Need the Most": Experiences of Loneliness in People With Inflammatory Arthritis: A Qualitative Study.
Int J Rheum Dis
January 2025
Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
Objective: Despite advancements in pharmacological treatments, living with inflammatory arthritis (IA) (including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA)) can make it challenging to engage in social activities, which may increase the risk of loneliness. Although loneliness is predominantly prevalent in IA, its origin and impact on mental health status on daily life with IA remain unexplored. Therefore, the objective of this study was to describe the experiences of people with IA in relation to loneliness.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!